AIMS: Claudin 2 (CLDN2) is a family of integral membrane tight junctions. The aim was to determine the influence of CLDN2 expression on tumour behaviour and its role in breast carcinogenesis. METHOD AND RESULTS: Thirty-seven invasive breast carcinomas and corresponding normal breast tissues were examined for CLDN2 protein and mRNA expression using Western blotting and semiquantitative reverse transcriptase-polymerase chain reaction. The expression of CLDN2 protein in 118 cases of breast carcinoma was further studied with immunohistochemistry and related to various clinicopathological parameters. CLDN2 protein expression was significantly down-regulated (0.4-fold) in tumours compared with corresponding normal breast tissue (P < 0.0001). Down-regulation of CLDN2 was significantly associated with lymph node metastasis (P = 0.047) by Western blot analysis, and with high clinical stage (P = 0.040) by immunohistochemistry. The expression levels of CLDN2 mRNA in high clinical stages (stages II and III) were lower than those in low clinical stage (stage I) and normal tissue, but not statistically significantly so. CONCLUSIONS: These results suggest that CLDN2 is implicated in the progression as well as the development of breast carcinoma, indicating that CLDN2 is a possible tumour suppressor gene product.
AIMS: Claudin 2 (CLDN2) is a family of integral membrane tight junctions. The aim was to determine the influence of CLDN2 expression on tumour behaviour and its role in breast carcinogenesis. METHOD AND RESULTS: Thirty-seven invasive breast carcinomas and corresponding normal breast tissues were examined for CLDN2 protein and mRNA expression using Western blotting and semiquantitative reverse transcriptase-polymerase chain reaction. The expression of CLDN2 protein in 118 cases of breast carcinoma was further studied with immunohistochemistry and related to various clinicopathological parameters. CLDN2 protein expression was significantly down-regulated (0.4-fold) in tumours compared with corresponding normal breast tissue (P < 0.0001). Down-regulation of CLDN2 was significantly associated with lymph node metastasis (P = 0.047) by Western blot analysis, and with high clinical stage (P = 0.040) by immunohistochemistry. The expression levels of CLDN2 mRNA in high clinical stages (stages II and III) were lower than those in low clinical stage (stage I) and normal tissue, but not statistically significantly so. CONCLUSIONS: These results suggest that CLDN2 is implicated in the progression as well as the development of breast carcinoma, indicating that CLDN2 is a possible tumour suppressor gene product.
Authors: Sébastien Tabariès; Fanny Dupuy; Zhifeng Dong; Anie Monast; Matthew G Annis; Jonathan Spicer; Lorenzo E Ferri; Atilla Omeroglu; Mark Basik; Eitan Amir; Mark Clemons; Peter M Siegel Journal: Mol Cell Biol Date: 2012-05-29 Impact factor: 4.272
Authors: A M Szasz; A M Tokes; M Micsinai; T Krenacs; Cs Jakab; L Lukacs; Zs Nemeth; Zs Baranyai; K Dede; L Madaras; J Kulka Journal: Clin Exp Metastasis Date: 2010-10-21 Impact factor: 5.150
Authors: Anna-Mária Tőkés; Attila Marcell Szász; Eva Juhász; Zsuzsa Schaff; László Harsányi; István Arthur Molnár; Zsolt Baranyai; István Besznyák; Attila Zaránd; Ferenc Salamon; Janina Kulka Journal: Pathol Oncol Res Date: 2011-12-23 Impact factor: 3.201
Authors: Ágnes Holczbauer; Benedek Gyöngyösi; Gábor Lotz; Attila Szijártó; Péter Kupcsulik; Zsuzsa Schaff; András Kiss Journal: J Histochem Cytochem Date: 2013-02-05 Impact factor: 2.479